Loading
Life sciences · Journal article
South Russian Journal of Therapeutic Practice · September 27, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Objective: to present the cardiological status and difficulties encountered in the management of a cardio-oncological patient in real clinical practice. Materials and methods: over a two-year period, a cardiological examination was performed on 243 patients with various malignant neoplasms (MN) referred from an oncological dispensary. The following categories of patients with cancer were analyzed: before chemotherapy (CT, n=47), during CT (n=149), before radiation therapy (n=10), before surgery (n=23), and with uncertain management (n=14). Results: patients with cancer who were referred to a cardiologist for initial risk assessment had significant cardiac comorbidity. Almost 70% of patients had two or more cardiovascular diseases before CT. Patients with cancer, regardless of the chemotherapy they received, were more likely to be classified as having a moderate risk of cardiovasculotoxicity (CVT). In the study sample, more than 40% of patients experienced various manifestations of CVT during their chemotherapy. The article describes the structure of CVT manifestations, both individually and depending on the specific chemotherapy drug used. It also highlights the challenges that cardiologists may face when assessing the risk of CVT, radiation-induced cardiotoxicity, and perioperative cardiovascular risk in patients with cancer. Conclusion: at the current stage, as part of the comprehensive management of patients with malignant neoplasms, a cardiologist should have extensive knowledge of the assessment of risk and clinical manifestations of various cardiovascular complications that occur during the use of antitumor treatment. This will allow for the effective implementation of the necessary therapy and improve the prognosis of patients with malignant neoplasms.